StockData
Alpha Cognition Inc. logo

Alpha Cognition Inc. (ACOG) company profile

ACOGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3064% above fair value
$7.92+0.09 (+1.15%)

Close on Nov 17, 2026Market cap $172.48MP/E –Yield –

About Alpha Cognition

Biological Products, (No Diagnostic Substances), SIC 2836

Alpha Cognition Inc. is a biopharmaceutical company that develops and commercializes therapies for neurodegenerative conditions, primarily Alzheimer’s disease. Its principal commercial offering is ZUNVEYL, an oral delayed-release tablet indicated for adults suffering from mild to moderate Alzheimer’s dementia. The company also pursues preclinical programs combining ZUNVEYL with memantine and developing sublingual formulations for cognitive impairment following mild traumatic brain injuries. Its target market comprises long-term care facilities, including nursing home physicians, healthcare teams, consultant pharmacists, and institutional pharmacies that care for elderly patients.

The company is headquartered in Grapevine, Texas, and is incorporated under the laws of British Columbia. Its commercial operations are based in the United States, where its medication is stocked and available through pharmacies nationwide. Alpha Cognition relies on contract manufacturing organizations in Taiwan for active pharmaceutical ingredients and facilities in the United States for tablet manufacturing. The company also holds an exclusive licensing agreement covering development and commercialization across Australia, New Zealand, and Asian territories excluding Japan.

Summary of the business section of Alpha Cognition's latest annual report, written by StockData.

Company profile

Company

Legal name
Alpha Cognition Inc.
Headquarters
Grapevine, TX
Address
1452 Hughes Rd., Ste. 200 76051
Phone
(858) 344-4375
Employees
72, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
A1
Fiscal year ends
December 31
Auditor
CBIZ CPAs P.C., New York, New York

Stock & identifiers

Ticker
ACOG
Exchange
Nasdaq
IPO date
Nov 13, 2024
Shares outstanding
22M, Aug 13, 2026
Public float
$149.50M, Jun 30, 2025
Filer category
<br>Emerging growth company
Stock splits
1-for-25 reverse, Nov 14, 2024
SEC CIK
1655923
CUSIP
02074J501
ISIN
CA02074J5017
FIGI
BBG011CJPRD0
Share class FIGI
BBG00L7TXNM1
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Michael E. McFaddenChief Executive Officer, Director204,691
Lauren D'AngeloChief Operating Officer140,695
Henry Huy DuVP Finance and Accounting20,579
Caren DeardorfDirector755
Robert James WillsDirector32,241
Bethany SensenigDirector5,489
Kenneth Anthony CawkellDirector225,717
Leonard Powell MertzDirector267,239
Phillip Joseph MertzDirector42,263
Rajeev Kumar BakshiDirector19,084
John Prentiss HavensDirector285,587

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsOtherTotalvs. prior year
Michael McFadden
Chief Executive Officer (1)
$625.00K$468.75K$2.50M$30.43K$3.62M+284%
Lauren D’Angelo
Chief Commercial Officer and Chief Operating Officer (3)
$500.00K$375.00K$1.50M$33.59K$2.41M+202%
Henry Du
Interim Chief Financial Officer (5)
$285.00K$147.93K–$31.58K$464.51K+28%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Nov 13, 2024
Offer price
$5.75
Exchange
Nasdaq
Lock-up ends (est.)
May 12, 2025

“333 -283126 8,695,653 Common Shares Pre-Funded Warrants to Purchase up to 8,695,653 Common Shares We are offering 8,695,653 common shares, no par value (the “common shares”) at an offering price of $ 5.75 per share We are also offering to each purchaser, with respect to the purchase of common shares that would otherwise result in the purchaser’s beneficial ownership exceeding 4.99% of our outstanding common shares immediately following the consummation of this offering, the o”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of March 30, 2026, we had 72 full-time employees”

Corporate history

Events identified from SEC filings

DateEventDetails
Oct 15, 2025Auditor changeChange in certifying accountant (8-K Item 4.01)
Oct 14, 2025Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 13, 2024IPOInitial public offering priced (424B4 prospectus)
Nov 8, 2024ListingRegistration of securities on an exchange (Form 8-A)
Oct 9, 2019Name changeName changed from Neurodyn Cognition Inc. to Alpha Cognition Inc.

See a number that looks wrong?